New biotech e-newsletter launching this Thursday. Don’t miss out.
Hey there. In the present day, we talk about the implications of the Supreme Courtroom’s forthcoming mifepristone analysis on the FDA and the biopharma business. We additionally look at how Covid-19 vaccine makers are faring as we speak, and extra.
The necessity-to-know this morning
- Novo Nordisk mentioned it could purchase the German agency Cardior Prescribed drugs in a deal price as much as $1.1 billion, choosing up extra drug candidates for its pipeline of cardiometabolic medicines.
- The Meals and Drug Administration rejected Regeneron Prescribed drugs’ bispecific antibody remedy for 2 sorts of blood most cancers, citing inadequate affected person enrollment in ongoing, confirmatory medical trials. Regeneron was looking for accelerated approval for its drug, referred to as odronextamab, however the FDA has beforehand warned drugmakers that accelerated approval is contingent on having confirmatory research considerably underway.
- Nuvation Bio mentioned it can acquire AnHeart Therapeutics, a privately held developer of most cancers medicine. Monetary phrases weren’t disclosed.
- Axsome Therapeutics mentioned its experimental drug referred to as AXS-12 achieved the goals of a Section 3 research in narcolepsy.
- Dyne Therapeutics mentioned CEO Joshua Brumm was leaving the company to pursue a profession in well being care investing. He will probably be changed by John Cox as Dyne’s new CEO and board member. Cox was previously CEO of Bioverativ.
Mifepristone case’s position in FDA, biopharma stability
Tomorrow, the Supreme Courtroom will hear the opening arguments over the destiny of abortion drug mifepristone. The case is of utmost significance to the biopharma business, and to the FDA: If the drug’s approval is upended, it might hobble the company’s authority for different medicines.
“It is a dagger on the coronary heart of the whole business,” one biopharma CEO instructed STAT. “I’d enterprise to guess that if [the ruling stood], the business will probably be thrown into full disarray.”
If the Supreme Courtroom unwinds the FDA’s approval determination for mifepristone, the priority is that advocates would possibly be capable to litigate in opposition to different regulatory selections.
“That is an abortion case however at root it’s an FDA case,” a medical ethicist instructed STAT. “I’m hopeful the Supreme Courtroom will acknowledge the enterprise implications.”
Learn extra.
The winners and losers of the pandemic vaccine race
The vaccines developed through the Covid-19 pandemic might have been too profitable. Though at first they represented windfalls for Pfizer, its associate BioNTech, and Moderna, traders now have a look at these revenues as not possible to duplicate. Though Pfizer vaccine gross sales exceeded $80 billion, its inventory value has dropped 30% over the previous 5 years. Merck, in distinction, noticed its vaccine efforts fail twice — however its inventory has jumped 65%.
STAT’s Matthew Herper seems in any respect the biopharma gamers that invested in pandemic vaccines, evaluating how firms like Pfizer, Sanofi, Johnson & Johnson, and Novavax are doing as we speak.
Learn extra.
Advocates debate the deserves of accelerated approval
Greater than three many years in the past, Yale professor Gregg Gonsalves and different AIDS activists lobbied to create the accelerated approval pathway. However now, he’s unsure that the velocity by which medicine are actually authorised is in the end serving to sufferers.
“We’re approving medicine sooner and sooner — [the FDA is] one of many quickest regulatory companies in thew world — we all know much less and fewer about them, and we pay increasingly more for them,” he mentioned throughout STAT’s Breakthrough Summit East in New York final week. “So in that manner, the system shouldn’t be working. We principally put entry on the market as this talisman of hope, however we don’t compel the businesses that give us solutions about what these medicine do in our our bodies.”
The position of affected person advocacy in drug improvement has grown more and more contentious lately, significantly with controversial approvals of Alzheimer’s and ALS medicine. Some are thrilled to have the possibility to take rapidly authorised medicines for ailments that will in any other case haven’t any remedy — whether or not or not the efficacy has been totally established. Security, for some, is sufficient. However there’s concern over whether or not dependable information is being generated in confirmatory research.
Learn extra.
Covid-19 antibody authorised for immunocompromised
The FDA authorised a brand new antibody drug to guard immunocompromised folks from Covid-19. The drug, Pemgarda, is the primary drug of this selection to develop into out there after regulators pulled AstraZeneca’s Evusheld off the market in January final yr for being ineffective in opposition to new Omicron variants. Sufferers with most cancers, autoimmune illness, and genetic issues, organ transplant recipients, and others have been anxious for a medication that may assist gird them in opposition to the quickly mutating virus.
It’s unclear what number of sufferers will use the prophylactic, although. Invivyd, the drug’s maker, mentioned there are 9 million immunocompromised folks within the U.S., however it can deal with the 485,000 who want it most acutely: Stem cell transplant recipients, organ transplant recipients, and blood most cancers sufferers.
“We are going to discover having it out there at our establishment, in order that our very compromised sufferers and the companies and specialities that care for these sufferers know that it’s an choice,” one infectious illness specialist instructed STAT. “However we’re not anticipating gangbusters by way of curiosity.”
Learn extra.
Extra reads
- Regardless of new Wegovy protection, Medicare sufferers might face excessive drug prices and different hurdles, STAT
- FDA grants full approval to AbbVie’s ovarian most cancers remedy, Reuters
- U.S.-China decoupling poses provide chain danger for drug firms, Wall Street Journal
- Intellia opts out of hemophilia B gene modifying work with Regeneron, FierceBiotech
